European Union - English - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influenza, human - vaccines - prophylaxis of influenza in the elderly (65 years of age and older).fluad tetra should be used in accordance with official recommendations.

United States - English - NLM (National Library of Medicine)

seqirus, inc. - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated) (unii: au5c98u4bb) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:c46xjt9fq9), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (formaldehyde inactivated) (unii: f5qv7af326) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:n969qk7xd2), influenza b virus b/austria/1359417/2021 bvr-26 antigen - fluad quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes a and types b contained in the vaccine. fluad quadrivalent is approved for use in persons 65 years of age and older. this indication is approved under accelerated approval based on the immune response elicited by fluad quadrivalent [see clinical studies (14.1)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. do not administer fluad quadrivalent to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine, including egg protein [see description (11)] , or to a previous influenza vaccine. risk summary fluad quadrivalent is not approved for use in persons < 65 years of age. there are insufficient human data to establish whether there is a vaccine-associated risk with use of fluad quadrivalent in pregnancy. there were no development

Canada - English - Health Canada

seqirus pty ltd - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b (victoria); haemagglutinin-strain b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - haemagglutinin-strain a (h1n1) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain b (victoria) 15mcg; haemagglutinin-strain b (yamagata) 15mcg - vaccines

Canada - English - Health Canada

seqirus pty ltd - haemagglutinin-strain a (h1n1); haemagglutinin-strain a (h3n2); haemagglutinin-strain b (victoria); haemagglutinin-strain b (yamagata) - suspension - 15mcg; 15mcg; 15mcg; 15mcg - haemagglutinin-strain a (h1n1) 15mcg; haemagglutinin-strain a (h3n2) 15mcg; haemagglutinin-strain b (victoria) 15mcg; haemagglutinin-strain b (yamagata) 15mcg - vaccines